DALLAS, July 31, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring biopharmaceutical company Ventana Biotech Inc. (Pink Sheets:VNTA). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Ventana Biotech Inc. (Pink Sheets:VNTA) should be of particular interest to other pharmaceutical companies: Generex Biotechnology Corp. (Nasdaq:GNBT), CPEX Pharmaceuticals Inc. (Nasdaq:CPEX), Mannkind Corp. (Nasdaq:MNKD) and Novo Nordisk A/S (NYSE:NVO).
It is available at: http://www.beaconequity.com/i/VNTA
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Ventana Biotech Inc. (VNTA) is a development-stage biopharmaceutical company engaged in research, development and commercialization of its proprietary therapeutic anti-obesity chewing gum treatment. The Company collaborates with drug researchers and developers, and intends to license its patented drug technologies to the large pharmaceutical or biotechnological companies.
In the report, the analyst notes:
"The Company operates in an approximately $21 billion oral anti-diabetic market and $61 billion weight-loss market, which are growing at roughly 6% per year. Research company Visiongain predicts continued significant market growth as the population in the OECD countries' median age climbs along with rates of obesity.
"The Company's flagship weight-loss chewing gum product is expected to enter pretrial drug trials. If approved by the U.S. Food and Drug Administration (FDA), its chewing gum will be included among 10 other competing anti-diabetes oral therapies in a worldwide multi-billion dollar weight-loss and diabetes market, which is expected to approximately double within 20 years."
To read the entire report visit: http://www.beaconequity.com/i/VNTA
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.